Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Compumedics Limited ( (AU:CMP) ).
Compumedics Limited has announced its financial performance for FY25, generating $51 million in revenue, with a projected revenue of over A$70 million and an EBITDA of approximately A$9 million for FY26. The company holds leading market positions in sleep and neurological diagnostics across various regions, including Australia, Japan, China, and the USA, and continues to expand its presence in the global medical technology market.
The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.
More about Compumedics Limited
Compumedics Limited is a global medical technology company specializing in sleep, neurological disorders, and ultrasonic brain blood flow monitoring. Founded in 1987 and listed on the ASX since 2000, the company has installed over 30,000 systems worldwide and operates offices in the USA, Germany, France, Austria, and Korea, with a network of over 100 distributors globally. Compumedics serves a blue-chip customer base, including hospitals, clinics, universities, and research organizations.
Average Trading Volume: 130,780
Technical Sentiment Signal: Buy
Current Market Cap: A$69.2M
For detailed information about CMP stock, go to TipRanks’ Stock Analysis page.